Atul Ltd
Atul Ltd
ChemicalsKey Fundamentals
SmallcapSpecialty ChemicalsChemicalsInsights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Atul Ltd insights
39 extracted metrics + investor summaries across FY04–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
3- Stock is trading at 3.18 times its book value
- The company has delivered a poor sales growth of 11.0% over past five years.
- Company has a low return on equity of 9.23% over last 3 years.
Growth Rate
AI Analysis — Bull vs Bear
Atul Ltd is a nearly debt-free specialty chemicals company with a market cap of ₹20,534 Cr trading at a PE of 25x. After several years of muted profit growth (5-year profit CAGR of just 1%), the company has shown a sharp TTM profit recovery of 59%, though its 3-year ROE of 9% remains below historical averages.
- Company is almost debt-free, providing significant financial flexibility and low interest burden
- TTM profit growth of 59% signals a strong earnings recovery after years of subdued performance
- TTM sales growth of 16% shows meaningful revenue acceleration compared to the 5-year sales CAGR of 11%
- 10-year stock CAGR of 13% demonstrates long-term value creation for shareholders
- 10-year compounded sales growth of 9% and profit growth of 9% indicate steady long-term business expansion
- Last year ROE of 11% shows improvement from the 3-year average of 9%, indicating margin recovery
- Dividend yield of 0.44% provides some income in a capital-intensive sector where many peers pay nothing
- 3-year ROE of only 9% is well below the 10-year average of 13%, indicating deteriorating capital efficiency
- 5-year stock CAGR of -5% means shareholders have seen capital erosion over a meaningful period
- 5-year compounded profit growth of just 1% suggests prolonged earnings stagnation prior to recent recovery
- Trading at 3.26x book value despite delivering sub-par ROE of 9% over 3 years raises valuation concerns
- 5-year compounded sales growth of 11% is modest for a specialty chemicals company at this valuation multiple
- PE of 25x is demanding given the inconsistent earnings track record over the last 5 years
- 3-year stock CAGR of just 1% indicates the market has not rewarded the company despite sector tailwinds
- ROE trending down from 13% (10-year) to 11% (5-year) to 9% (3-year) shows a structural decline in return ratios
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Q1 profit surges 106% YoY Jul 25
Consolidated net profit jumped 106% YoY to ₹253.93 crore in Q1FY26, driven by 25% revenue increase to ₹1,847.95 crore. Performance and Other Chemicals segment was the key growth driver.
- AGM approves dividend, key appointments Aug 1
All five resolutions passed at the 49th AGM on July 31, 2026, including FY26 financials adoption, dividend declaration, and reappointment of Samveg Lalbhai as MD for five years.
- ₹167 cr capex for herbicides Jul 24
Board approved ₹167 crore investment for new MCPP-p (1,000 TPA) and MCPA (750 TPA) manufacturing units, funded via internal accruals, to be completed within 67 weeks.
- Independent Director postal ballot Aug 6
Postal ballot initiated to appoint Vinayak Deshpande as Independent Director for a five-year term. Voting window runs August 7 to September 5, 2026.
- ₹61.75 cr block trade on BSE Jul 21
Approximately 1,00,000 shares transacted in a single block deal at ₹6,175 per share on BSE, totalling ₹61.75 crore, indicating institutional-level participation.
- Two senior VPs appointed Jul 20
Dhaval Vashi (Pharmaceuticals) and Vinay Desai (Technology & Manufacturing) appointed as Senior Vice Presidents effective July 18, 2026.
TL;DR: Atul Ltd is delivering strong operational momentum with Q1 profit more than doubling on robust revenue growth. Capex approval for phenoxy herbicides signals confidence in expanding the agrochemicals portfolio. No material headwinds are visible in recent news flow. The trend is clearly improving, and execution on the new capacity addition over the next 67 weeks will be the key monitorable.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,182 | 1,194 | 1,138 | 1,212 | 1,322 | 1,393 | 1,417 | 1,452 | 1,478 | 1,552 | 1,574 | 1,670 | 1,848 |
| Expenses | 1,000 | 1,039 | 986 | 1,065 | 1,099 | 1,150 | 1,193 | 1,229 | 1,242 | 1,284 | 1,327 | 1,389 | 1,454 |
| Operating Profit | 182 | 155 | 152 | 148 | 223 | 243 | 224 | 223 | 236 | 267 | 247 | 281 | 394 |
| OPM % | 15% | 13% | 13% | 12% | 17% | 17% | 16% | 15% | 16% | 17% | 16% | 17% | 21% |
| Other Income | 10 | 24 | 17 | 16 | 16 | 35 | 19 | 50 | 28 | 50 | 40 | 92 | 35 |
| Interest | 2 | 2 | 2 | 5 | 5 | 9 | 4 | 5 | 5 | 5 | 4 | 4 | 4 |
| Depreciation | 52 | 54 | 61 | 76 | 77 | 78 | 81 | 82 | 82 | 81 | 80 | 79 | 78 |
| PBT | 138 | 124 | 105 | 83 | 158 | 191 | 158 | 186 | 177 | 231 | 203 | 289 | 347 |
| Tax % | 26% | 26% | 32% | 29% | 29% | 27% | 26% | 30% | 25% | 21% | 20% | 27% | 27% |
| Net Profit | 102 | 91 | 72 | 59 | 112 | 140 | 117 | 130 | 132 | 182 | 164 | 211 | 254 |
| EPS in Rs | 35.02 | 30.6 | 24.04 | 19.84 | 38 | 46.47 | 36.93 | 42.97 | 43.4 | 60.88 | 54.6 | 71.38 | 83.32 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,637 | 2,595 | 2,834 | 3,514 | 4,038 | 4,093 | 3,731 | 5,081 | 5,428 | 4,726 | 5,583 | 6,274 | 6,643 |
| Expenses | 2,235 | 2,134 | 2,324 | 3,008 | 3,270 | 3,191 | 2,813 | 4,168 | 4,620 | 4,086 | 4,665 | 5,240 | 5,455 |
| Operating Profit | 402 | 461 | 510 | 505 | 768 | 902 | 918 | 913 | 807 | 639 | 918 | 1,034 | 1,189 |
| OPM % | 15% | 18% | 18% | 14% | 19% | 22% | 25% | 18% | 15% | 14% | 16% | 16% | 18% |
| Other Income | 9 | 37 | 57 | 30 | 38 | 83 | 109 | 82 | 86 | 65 | 115 | 206 | 217 |
| Interest | 26 | 28 | 25 | 13 | 7 | 9 | 9 | 9 | 8 | 11 | 24 | 17 | 17 |
| Depreciation | 60 | 66 | 95 | 110 | 119 | 130 | 136 | 177 | 198 | 243 | 317 | 322 | 318 |
| PBT | 326 | 404 | 446 | 412 | 680 | 845 | 882 | 810 | 688 | 451 | 692 | 900 | 1,070 |
| Tax % | 31% | 32% | 28% | 32% | 36% | 21% | 25% | 25% | 26% | 28% | 28% | 23% | — |
| Net Profit | 240 | 274 | 323 | 281 | 436 | 671 | 660 | 605 | 507 | 324 | 499 | 689 | 811 |
| EPS in Rs | 81.13 | 92.44 | 109 | 93.21 | 146 | 225 | 222 | 204 | 174 | 110 | 164 | 230 | 270 |
| Div. Payout % | 10% | 9% | 9% | 13% | 10% | 12% | 9% | 12% | 19% | 18% | 15% | 13% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 29 | 29 | 29 |
| Reserves | 1,009 | 1,585 | 1,936 | 2,214 | 2,676 | 3,125 | 3,797 | 4,399 | 4,642 | 5,085 | 5,569 | 6,192 |
| Borrowings | 299 | 316 | 168 | 16 | 55 | 108 | 127 | 144 | 52 | 237 | 202 | 183 |
| Other Liabilities | 485 | 535 | 591 | 749 | 783 | 880 | 982 | 1,117 | 1,028 | 1,104 | 1,179 | 1,465 |
| Total Liabilities | 1,823 | 2,465 | 2,724 | 3,009 | 3,543 | 4,144 | 4,935 | 5,690 | 5,752 | 6,455 | 6,980 | 7,870 |
| Fixed Assets | 514 | 750 | 1,026 | 1,027 | 1,104 | 1,125 | 1,418 | 1,634 | 1,770 | 2,792 | 2,847 | 2,676 |
| CWIP | 112 | 180 | 59 | 96 | 172 | 368 | 250 | 420 | 1,033 | 281 | 124 | 110 |
| Investments | 66 | 382 | 429 | 470 | 752 | 1,137 | 1,361 | 1,339 | 881 | 1,392 | 1,766 | 2,592 |
| Other Assets | 1,131 | 1,154 | 1,210 | 1,415 | 1,515 | 1,513 | 1,906 | 2,297 | 2,068 | 1,990 | 2,242 | 2,492 |
| Total Assets | 1,823 | 2,465 | 2,724 | 3,009 | 3,543 | 4,144 | 4,935 | 5,690 | 5,752 | 6,455 | 6,980 | 7,870 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 306 | 401 | 392 | 356 | 404 | 881 | 718 | 231 | 707 | 667 | 603 | 1,023 |
| Investing | -167 | -375 | -175 | -129 | -408 | -782 | -645 | -163 | -469 | -683 | -494 | -891 |
| Financing | -124 | -39 | -212 | -207 | -1 | -111 | -52 | -57 | -257 | 38 | -118 | -98 |
| Net Cash Flow | 16 | -13 | 5 | 19 | -5 | -11 | 21 | 11 | -20 | 22 | -9 | 34 |
| Free Cash Flow | 111 | 31 | 180 | 213 | 195 | 508 | 396 | -359 | -167 | 164 | 334 | 851 |
| CFO/OP | 95 | 111 | 93 | 91 | 86 | 122 | 100 | 47 | 112 | 121 | 82 | 113 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 62 | 67 | 75 | 63 | 64 | 72 | 71 | 57 | 72 | 74 | 74 |
| Inventory Days | 105 | 118 | 107 | 83 | 89 | 93 | 128 | 122 | 101 | 90 | 97 | 90 |
| Days Payable | 69 | 87 | 86 | 93 | 66 | 88 | 121 | 90 | 69 | 84 | 82 | 94 |
| Cash Conversion Cycle | 97 | 93 | 88 | 66 | 86 | 69 | 78 | 103 | 89 | 77 | 89 | 70 |
| Working Capital Days | 50 | 46 | 65 | 76 | 74 | 59 | 65 | 77 | 68 | 69 | 77 | 69 |
| ROCE % | 26% | 26% | 23% | 19% | 27% | 28% | 24% | 19% | 15% | 9% | 13% | 15% |
Documents
Frequently Asked Questions about Atul Ltd
What does Atul Ltd do?
Where is Atul Ltd (ATUL) listed?
Which sector does Atul Ltd belong to?
What is the market capitalisation of Atul Ltd?
What is the PE ratio of Atul Ltd?
What is the 52-week high and low of Atul Ltd?
Does Atul Ltd pay dividends?
What is the Return on Equity (ROE) of Atul Ltd?
How can I research Atul Ltd on Tapetide?
Company Information
Atul Ltd. is a diversified and integrated Indian chemical company (a part of Lalbhai Group, Gujarat). The products of the company are used in various Industries and come mainly under two segments, Life Science Chemicals and Performance and Other Chemicals under 9 Businesses. [1] Since its incorporation, the company has manufactured many products for the first time in India Dyes including Vat Dyes, crop care chemicals, Phosgene, Carbamite, 2,4-D Acid, para Cresol, tissue culture raised date palms. [2]